evipedia.ai
← Back

Low-Level Light Therapy for Hair Regrowth

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Low-level light therapy is a home device treatment: combs, caps and helmets shining low-power red light on the scalp to regrow hair in hereditary pattern thinning. Trials against look-alike devices show more and thicker hairs after four to six months in men and women, though whether users can see the gain is less certain. Risks appear small, many trials are tied to device makers, and benefit depends on ongoing use. (Full Review)

Protocol

Handheld laser comb (HairMax, Lexington International)
Three times weekly, 8–15 minutes
655 nm comb passed over the whole scalp, for 26 weeks
Laser/LED helmet (TOPHAT 655, Apira Science)
25 minutes every other day
21 lasers plus 30 LEDs at 655 nm, for 16 weeks (60 treatments)
Lower-frequency alternative
Every other day or three times weekly
Low-frequency regimens outperformed high-frequency ones; an alternative to daily use rather than a lesser option
Time to effect
Hair-count gains
By 16 weeks
Clearer at 24–26 weeks; judging results before 6 months risks a false negative conclusion
Thicker hair shafts
16 weeks
Shafts thickened versus sham
Regrowth after chemotherapy
Within a month
Of finishing chemotherapy, with three weekly sessions

Benefits

Contraindications
  • Within 30 days of porfimer administration
  • Within 48 hours of aminolevulinic acid photodynamic therapy on the treated scalp areas
  • Undiagnosed, changing or active skin cancer on the treated area (inferred from cell studies)
  • Photosensitive epilepsy, using pulsed visible-light devices (inferred; no human data)
  • Light-sensitive porphyrias (erythropoietic protoporphyria, porphyria cutanea tarda; inferred; no human data)
    •
Key Interactions
  • Topical minoxidil (over the counter): no increase in adverse events with 5% minoxidil; added benefit is inconsistent
  • Microneedling and platelet-rich plasma injections (other interventions): no interaction data; light sessions spaced 24–48 hours after procedures
    •
Theoretical (inferred from mechanism)
  • Systemic photosensitizing drugs (doxycycline, isotretinoin): additive light sensitivity could cause scalp redness or burning
  • St John's wort (supplement): additive photosensitivity could cause scalp redness or burning
  • Hair-growth supplements with additive effect (saw palmetto, pumpkin seed oil): density effects could add without harm
  • Topical tretinoin or other scalp irritants (over the counter salicylic acid shampoos): additive irritation could cause redness and stinging
  • Oral finasteride or dutasteride (5-alpha-reductase inhibitors): additive regrowth suggested
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Temporary hair shedding; mild scalp irritation; headache
    •
  • Speculative: Eye injury from direct beam exposure; stimulation of scalp skin cancers
    •

Monitoring

Marker Target Why
Terminal hair density (hairs/cm²) No established target; track change from own baseline at the same site Primary response marker
Hair shaft diameter (µm) No established target; track change from own baseline Thickening adds coverage
Standardized global photographs No established target; compare with own baseline images Shows visible coverage
Scalp skin examination No established target; track new, changing or rough lesions Safety check: a suspicious lesion pauses use over that area

Cadence: Baseline, then at 3 months, 6 months and every 6–12 months; scalp examination yearly or whenever a lesion appears

Qualitative Assessment

  • Less hair on the pillow, brush and shower drain
  • Narrower part width and fuller appearance in photographs
  • Easier styling and less visible scalp under bright light
  • Self-rated satisfaction at 6 months
  • Scalp comfort: absence of itching, redness or warmth after sessions
  • Absence of headaches during or after sessions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.